We are live on ! Find out more
UNCY icon

Unicycive Therapeutics

95 hedge funds and large institutions have $53.5M invested in Unicycive Therapeutics in 2026 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 11

124% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 17

20% more funds holding

Funds holding: 79 → 95 (+16)

4% less capital inflows, than outflows

Capital inflows: $14.5M | Capital outflows: $15.1M

10% less call options, than puts

Call options by funds: $2.11M | Put options by funds: $2.34M

1.44% less ownership

Funds ownership: 42.39% → 40.95% (-1.4%)

Holders
95
Holders Change
+16
Holders Change %
+20.25%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
38
Reduced
17
Closed
11
Calls
$2.11​M
Puts
$2.34​M
Net Calls
-⁠$228​K
Net Calls Change
-⁠$4.81​M

UNCY Hedge Fund Activity: Q3 2026 in Review

95 of the 8,220 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2026, worth a combined $53.5M — down 2% from $54.6M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new UNCY positions and 11 closed out — a net gain of 16 holders — while 38 added to existing stakes and 17 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $2.01M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.76M.

  • 95 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2026, up from 79 in Q2 2026.
  • Funds reported $53.5M of Unicycive Therapeutics stock for Q3 2026, down 2% quarter-over-quarter.
  • 27 funds opened new Unicycive Therapeutics positions in Q3 2026 and 11 closed out, a net change of +16 holders.
  • The largest Unicycive Therapeutics buyer in Q3 2026 was OrbiMed, an estimated $2.01M added.
  • The largest Unicycive Therapeutics seller in Q3 2026 was Octagon Capital Advisors, an estimated $3.76M sold.

Based on aggregated 13F filings for Q3 2026.